Table 1.
Anti-RBD antibody titres after two doses BNT162b2
| Anti-RBD antibody titres (AU/mL), median (IQR) |
|||||
|---|---|---|---|---|---|
| N (%) | 1.5 months after second dose of BMT162b2 | p value | 3 months after second dose of BMT162b2 | p value | |
| All | 230 (100) | 9356 (5844–16 876) |
— | 3952 (2190–8561) |
<0.001 |
| Sex | |||||
| Male | 143 (62) | 10 293 (6155–17 292) |
0.323 | 4292 (2053–11 356) |
0.454 |
| Female | 87 (38) | 8434 (5751–16 449) |
3797 (2206–7711) |
||
| Previous SARS-CoV-2 infection | |||||
| Yes | 36 (16) | 19 016 (7974–27 885) |
<0.001 | 9364 (3975–22 233) |
<0.001 |
| No | 194 (84) | 8747 (5631–15 409) |
3724 (2003–7137) |
||
| Age (years) | |||||
| 20–30 | 29 (12.6) | 15 402 (8763–21 545) |
5733 (3893–12 891) |
||
| 31–40 | 47 (20.4) | 7642 (5683–13 532) |
2949 (1981–8950) |
||
| 41–50 | 68 (29.6) | 9272 (5432–16 589) |
0.046 | 3572 (1721–6771) |
0.023 |
| 51–60 | 60 (26.1) | 9234 (6251–17 180) |
3862 (2285–7824) |
||
| 61–70 | 25 (10.9) | 9262 (4541–16 081) |
6176 (2193–14 392) |
||
| 71–80 | 1 (0.4) | 2165 | 750 | ||
Abbreviations: anti-RBD, antibody against the receptor binding domain of the S1 subunit of the spike protein of SARS-CoV-2; IQR, interquartile range; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.